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Background: Primary gallbladder carcinoma (GBC) is associated with poor prognosis. This study aimed to
clarify the age-speciﬁc clinical characteristics of primary GBC among elderly patients.
Methods: We retrospectively reviewed the medical records of patients with GBC treated in Mackay
Memorial Hospital, Taipei, Taiwan over a period of 10 years, from 2003 to 2012. Patients aged 65 years or
older at the time of diagnosis of primary GBC were deﬁned as the elderly group. According to the Kaplan
eMeier method, survival curves were compared between patients receiving surgical treatment or not.
Results: In total, 64 patients with primary GBC were reviewed. Forty-eight patients (75%) were included
in the elderly group. Mean age of the patients at the time of diagnosis was 77.8 ± 7.1 years. Compared
with young group, the serum level of carcinoembryonic antigen was signiﬁcantly higher (p ¼ 0.025) and
hemoglobin was signiﬁcantly lower (p ¼ 0.025) in the elderly group. The percentages of elderly patients
in the tumorenodeemetastasis (TNM) Stages 0eIII and IV were 50.0%, and 50.0%, respectively. Twenty-
six patients received surgical resection. The cumulative survival curves of the surgical intervention and
nonsurgical intervention groups differed signiﬁcantly for elderly patients in the TNM Stages 0eIII
(p ¼ 0.002) and Stage IV (p ¼ 0.041).
Conclusion: Most elderly patients at the time of diagnosis of GBC were in TNM Stage IV. Surgery was the
predominant treatment at our hospital. Surgical interventions might be associated with better survival
for elderly patients with GBC.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Primary gallbladder carcinoma (GBC) is relatively rare, although
it is the most common biliary tract cancer1,2. Due to the low inci-
dence and the lack of recognized symptoms, GBC patients often
have advanced disease when diagnosed, leading to a poor prog-
nosis and high mortality rate. The risk of developing GBC is known
to be age dependent;3 therefore, an increased number of elderlyre that they have no conﬂicts
ision of Gastroenterology,
Hospital, Number 92, Section
hen).
tric Emergency & Critical Care Mepatients will be diagnosed with GBC in the coming years owing to
the general increase in the population longevity. The only effective
and potential curative treatment is surgery. However, the majority
of instances the lesions are considered unresectable at the time of
surgical exploration because of local invasion into critical structures
or metastases beyond locoregional conﬁnes. In these situations,
treatment is palliative in nature. The goals of palliation for
advanced GBC are relief of pain, jaundice, and bowel obstruction,
and prolongation of life1,2.
The elderly are usually deﬁned as to be aged 65 years and older.
Approximately 60% percent of new cases and 70% of mortality from
cancer occur in patients older than 65 years4e6. As a result, the care
of older patients constitutes an important part of everyday clinical
practice. Compared with younger age patients, the elderly group
shows signiﬁcantly higher comorbidity, particularly withdicine. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1. Age distribution of the patients with primary gallbladder carcinoma.
Gallbladder Carcinoma in Elderly Patients 229pulmonary and cardiovascular diseases7. Due to the fact that
treatment is often withheld from them for fear of potential toxic-
ities or perceived minimal survival beneﬁt, many elderly patients
do not receive optimal cancer treatment4e6. Hence, clarifying the
optimal treatment strategy for elderly patients with GBC has
become an urgent necessity. To our knowledge, there have been
few studies evaluating elderly patients with GBC. In this study, our
aim was to clarify the age-speciﬁc clinical characteristics of GBC,
and to evaluate the survival and characteristics of elderly patients
with GBC aged over 65 years retrospectively.
2. Materials and methods
From January 2003 to December 2012, a total of 99 patients
were diagnosed with GBC at MacKay Memorial Hospital, Taipei,
Taiwan. Patients aged 65 years or older at the time of diagnosis of
primary GBC were deﬁned as the elderly group.
For each patient, the following data were recorded by retro-
spective chart review: patient demographics; presence of medical
comorbidities; symptoms at presentation; biochemical analysis;
serum carbohydrate antigen (CA19-9) and carcinoembryonic anti-
gen (CEA) level; tumor staging; initial therapy; extents of resection;
pathology; and survival. The imaging studies included abdominal
ultrasonography, computed tomography, magnetic resonance im-
aging, magnetic resonance cholangiopancreatography, and endo-
scopic retrograde cholangiopancreatography. The follow-up end
point was December 2013. The medical records of 35 patients did
not contain sufﬁcient information and those patients were
excluded from this report. The series consists of the remaining 64
patients who were treated, and the data concerning these patients
were reviewed retrospectively. The treatments were performed
according to the current guidelines for treatment of GBC1,2,8. Per-
formance status was not disclosed because many patients lacked
this information.
The 7th edition of the American Joint Committee on cancer
staging system was used for tumorenodeemetastasis (TNM) can-
cer staging9. The types of initial treatment for GBCwere categorized
into four categories: (1) surgical resection, extended surgery, and
palliative surgery; (2) systemic chemotherapy; (3) radiotherapy;
and (4) supportive care. Extended surgery was deﬁned as chole-
cystectomy with one or more of the following procedures: liver
resection (partial hepatectomy or resection of gallbladder fossa),
lymph node dissection along the hepatoduodenal ligament,
resection of extrahepatic bile duct. Palliative surgery included
cholecystostomy, tube drainage of the bile duct, or biopsy of the
tumor only. Cholecystectomywas deﬁned as cholecystectomy alone
or cholecystectomy with drainage of the bile duct. The TNM stage
categories were grouped as 0eIII and IV for statistical analysis
because of the low number of patients within such categories.
According to the KaplaneMeier method, survival curve were
compared between patients receiving surgery or not. This study
was approved by the Institute Review Board of MacKay Memorial
Hospital.
2.1. Statistical analysis
The data are expressed as the mean ± standard deviation for
continuous variables and n (%) for categorical variables. Statistical
analyses were carried out using the Student t test for unpaired
continuous data, or c2 test or Fisher's exact test as appropriate for
categorical data. The cumulative survival curves according to the
KaplaneMeier method were compared using the log-rank test. A p
value < 0.05 was considered to represent statistical signiﬁcance. All
statistical analyses were performed using the SPSS version 21.0
software package (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Demographic characteristics of the study population
A total of 64 consecutive patients were enrolled in this study.
The age distribution of patients with GBC is shown in Figure 1. The
most common symptom was epigastric pain (55%), followed by
right upper quadrate pain (23%), jaundice (23%), and nausea/
vomiting (23%; Table 1). The demographic and characteristics of
the patients with GBC are summarized in Table 2. The mean age of
the 64 patients with GBC at the time of diagnosis was 70.9 ± 13.4
years (range, 36e92 years; median, 73 years). Most patients with
GBC had gallstone (60%) and thickened gallbladder (GB) wall (>
3 mm; 47.4%). Forty-eight patients (75%) were older than 65 years
(elderly group). Mean age of the elderly patients at the time of
diagnosis was 77.2 ± 7.4 years. The sex ratio (male to female) was
17:31. There were no signiﬁcant difference between the elderly
and young groups in sex, gallstone, thickened GB wall, or GB
polyps. However, compared with young patients, there was a
trend increase in the proportion of elderly patients in recent years
(data not shown).
On biochemical analysis (Table 3), there was signiﬁcantly lower
level of hemoglobin in the elderly group compared with young
group (p ¼ 0.025). The level of CEAwas signiﬁcant higher in elderly
group compared with young group (p ¼ 0.025). Most of the histo-
logically proven GBC (94.3%) were adenocarcinomas and the others
were undifferentiated carcinoma (data not shown).
3.2. Therapeutic management and outcome of GBC
There was no signiﬁcant difference between the elderly and
young groups in mortality at the end of the follow-up time
(Table 2). The overall 5-year survival rate was 9.4% (n ¼ 6). Table 4
shows the initial treatment modalities for these elderly patients.
The percentages of elderly patients in the TNM Stages IeIII and IV
were 50.0%, and 50.0%, respectively. A total of 26 patients under-
went surgery treatment. TNM Stages IIIa þ IIIb (n ¼ 10, 38.5%) was
the most frequent group. Most of these 26 patients received sur-
gical interventions; the portion of the surgical resection, extended
surgery, and palliative surgery was 69.2%, 26.9%, and 3.8%, respec-
tively. Twenty-two patients received nonsurgery treatment; the
portion of chemotherapy, radiotherapy, and supportive care was
Table 1
Clinical presentation of the patients with primary gallbladder
carcinoma.a
Symptom/sign n (%)
Abdominal pain 50 (78)
Right upper quadrant pain 15 (23)
Epigastralgia 35 (55)
Jaundiceb 15 (23)
Fever and chills 13 (20)
Nausea and vomiting 15 (23)
Abdominal mass 1 (2)
Abdominal distension 6 (9)
Weight loss 9 (14)
Constipation 2 (3)
a The initial presentation at the time of diagnosis of primary
gallbladder carcinoma.
b At least one presentation of clinical jaundice, including yellow
skin, icteric sclera, pale stool, and tea color urine.
Table 4
Type of initial treatment for elderly patients with primary gallbladder carcinoma in
different tumorenodeemetastasis (TNM) stage.
Treatment Total TNM Stage
0 I II IIIa þ IIIb Iva þ IVb
Surgery 26 1 1 6 10 8
Surgical resection 18 1 1 5 5 6
Extended surgery 7 0 0 1 5 1
Palliative surgery 1 0 0 0 0 1
Chemotherapy 8 0 0 2 2 4
Radiotherapy 1 0 0 0 0 1
Supportive care 13 0 0 0 2 11
C.-W. Chang et al.23036.3%, 4.5%, and 59%, respectively. TNM Stages IVa þ IVb (n ¼ 16,
72.7%) was the most frequent group.
For patients with GBC, there were signiﬁcant difference in cu-
mulative survival curves of surgical intervention and nonsurgical
intervention group in TNM Stages 0eIII (p < 0.001) and Stage IV
(p ¼ 0.006). There were no differences between young and elderly
in the same surgical and nonsurgical group, p¼ 0.141 and p¼ 0.935,
respectively. For elderly patients with GBC, there are also signiﬁcantTable 2
Characteristics of patients with primary carcinoma of the gallbladder.a
All patients
No. of patients 64
Age (y) 70.9 ± 13.4 (36e92)
Sex (male/female) 24/40
Diabetes mellitus 26 (41.3)
Hyperlipidemia 4 (6.3)
Gallbladder stone 36/60 (60)
Gallbladder wall thickness, > 3 mm 28/59 (47.4)
Common bile duct stone 4/50 (8)
Gallbladder polyps 6/57 (10.5)
Stage
0 þ I þ II þ IIIa þ IIIb 31
IVa þ IVb 33
Deathb 53/64 (82.8)
Data are presented as n (%) or n/N (%) or mean ± standard deviation (range).
* Statistically different (p < 0.05).
a At the time of diagnosis of primary gallbladder carcinoma.
b Percentage of death in patients with primary gallbladder carcinoma at the end of fo
Table 3
Comparison in patients with primary gallbladder carcinoma between elderly and young
All patients
Hemoglobin (g/dL) 11.08 ± 2.24
Hematocrit (%) 32.73 ± 6.69
WBC ( 109/L) 11.39 ± 6.38
SGOT (U/L) 103.06 ± 158.82
SGPT (U/L) 115.23 ± 182.84
Alkaline phosphatase (U/L) 196.89 ± 180.97
Bilirubin (mg%) 4.31 ± 6.82
Direct 2.21 ± 4.02
Indirect 1.81 ± 2.66
CEA (ng/mL) 56.86 ± 109.55
CA 199 (U/mL) 11,143 ± 26,132
Data are presented as mean ± standard deviation.
CA¼ cancer antigen; CEA¼ carcinoembryonic antigen; SGOT¼ serum glutamiceoxaloace
cells.
* Statistically different (p < 0.05).
a At the time of diagnosis of primary gallbladder carcinoma.difference in cumulative survival curves of surgical intervention
and nonsurgical intervention group for elderly patients with GBC in
TNM Stages 0eIII (Figure 2A, p ¼ 0.002) and Stage IV (Figure 2B,
p ¼ 0.041).
4. Discussion
Our study showed that most elderly patients at the time of
diagnosis of GBC were at late stage of disease (TNM Stage IV).
Surgery was the predominant treatment for these patients. Surgical
interventions for GBC, especially in TNM Stages 0eIII and even
Stage IV, might improve the survival rate. Therefore, surgical
treatment was important to improve elderly patients with GBC.Age 65 y Age< 65 y p
48 16
77.2 ± 7.4 (65e92) 51.9 ± 8.2 (36e64)
17/31 7/9 0.551
21 (45.6) 5 (29.4) 0.077
3 (6.5) 1 (5.6) > 0.999
28/44 (63.6) 8/16 (50) 0.480
23/43 (53.5) 5/16 (31.3) 0.509
4/37 (10.8) 0 > 0.999
3/41 (7.3) 3/16 (18.8) 0.138
24 7
24 9
42/48 (87.5) 11/16 (68.8) 0.124
llow-up period.
groups.a
Age  65 y Age < 65 y p
10.72 ± 2.13 12.20 ± 2.29 0.025*
31.68 ± 6.47 35.95 ± 6.54 0.031*
12.04 ± 6.84 9.37 ± 4.31 0.163
97.59 ± 169.65 118.81 ± 126.02 0.649
96.55 ± 184.60 171.29 ± 171.61 0.188
173.51 ± 159.26 265.08 ± 227.49 0.217
4.50 ± 7.26 3.69 ± 5.31 0.699
2.24 ± 4.23 2.12 ± 3.39 0.921
1.82 ± 2.84 1.80 ± 2.07 0.983
67.57 ± 117.47 3.31 ± 4.27 0.025*
8952 ± 23,917 19,539 ± 34,647 0.387
tic transaminase; SGPT¼ serum glutamic-pyruvic transaminase;WBC¼white blood
Figure 2. Survival curves of surgical interventions for elderly patient with primary
gallbladder carcinoma in TNM Stage (A) 0eIII and (B) IV (statistically signiﬁcantly
different, p < 0.05).
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in younger people. Women who have increased exposure to es-
trogen are affected 2e6 times more often than men8. Several risk
factors have been identiﬁed, many of which share a common
characteristic of chronic GB inﬂammation: gallstone disease, GB
polyps and congenital biliary cysts, anomalous pancreaticobiliary
junction, and chronic infection1. The most important risk factor is
cholelithiasis and up to 90% of GBCs are associated with gallstones2.
In our study, GBC was more common in elderly patients, women,
and patients with gallstones and thickened GB wall.
Our study showed the prognosis of GBC is poor with 5-year
survival 9.4%. Most studies also show that GBC is very poor with
5-year survival 0e10%1,2. The GB wall has mucosa, lamina propria,
thin muscular layer, perimuscular connective tissue, and serosa, it
lacks muscular mucosa. It does not have serosal covering at the
portion of the GB adjacent to the liver and the perimuscular con-
nective tissue is continuous with hepatic connective tissue. Thus,
GBC has a high rate of metastasis and there are several pathways to
spread easily, including direct invasion and lymphatic, vascular,
neural, intraperitoneal, and intraductal metastasis. Therefore, the
liver is the most commonly affected organ by direct invasion, fol-
lowed by regional lymph node metastasis10.
Several factors have been evaluated to predict the survival of
patients with primary GBC1,11e13. Incidental detection of GBC at the
time of routine cholecystectomy for gallstones carries a good
prognosis. Tumor size, depth of invasion and lymph node
involvement are associated with poor prognosis14. A destructive
pattern of invasion has been shown to have a poorer outcome
compared with inﬁltrative pattern. At histology, poorly differenti-
ated malignancy, presence of perineural and perivascular invasion,
GLUT-1 expression, mutations in p53, p21, p16, and p27 genes are
associated with poorer survival15. The most important of these
factors is the depth of the invasion, which is directly proportional
with the odds of lymphatic invasion, and the histological grade16.
Single-center medical records of 102 patients with GBC showed the
only independent factor in multivariate analysis to be liver
involvement17. Wang et al13 concluded that stage and surgical
approach are independent prognostic factors for GBC. One study
analyzed the prognostic factors of 87 patients with GBC and found
that the presence of palpable mass, types of surgical treatment, and
age were also predictors of survival by multivariate analysis. In
addition, these three factors were also signiﬁcant in Stage IV dis-
ease18. These ﬁndings suggested that resectional surgery was
associated with better survival for patients with all stages of thedisease, including those with advanced GBC. Other studies failed to
identify age as a prognostic factor19e21. Butte et al11 analyzed GBC
patients in three centers and only T-stage, nodal involvement, and
bile duct involvement were predictors of survival on multivariate
analysis. Surgical interventions did not result in signiﬁcant differ-
ences11. In our study, surgical interventions were associated with
better survival for GBC patients, including elderly patients, with all
stages of the disease.
The most common and most effective treatment is surgical
removal of the GB with part of liver and lymph node dissection1,2,11.
If the cancer has spread and cannot be removed, palliative surgery
may relieve symptoms including surgical biliary bypass, endoscopic
stent placement, and percutaneous transhepatic biliary drainage.
Moreover, chemotherapy and radiation may also be used for pa-
tients with advanced and unresectable GBC. Systemic chemo-
therapy has been shown to have superior impact on survival, versus
supportive care alone. Gemcitabine and 5-ﬂourouracil as mono-
therapy or in combination are ﬁrst line therapy for treatment of
unresectable GBC. Data from clinical trials combining gemcitabine
with capecitabine22 and oxaliplatin23 reveal the evidence of pro-
longed survival when compared with supportive care. Combination
therapy using 5-ﬂourouracil with cisplatin gave survival advan-
tage24,25. There are very few data on the outcome of radiotherapy
alone for unresectable GBC1. Furthermore, whether the use of
chemoradiotherapy favorably impacts survival in the unresectable
GBC continues to be debated.
Surgical procedures for patients with GBC are still controversial.
The approach depends on the stage of the disease, the availability of
local expertise, patient's performance status and whether preop-
erative diagnosis was suspected or not. There has been increasing
emphasis on aggressive surgery for patients with GBC8,15,26. For
patients with Tis (carcinoma in situ) and T1a (tumor invades lamina
propria) diseases, it is universally accepted that simple cholecys-
tectomy is sufﬁcient therapy. In T1b tumors invade the muscular
layer, some studies support simple cholecystectomy and others
suggest radical resection. T2 cancers are best treated with chole-
cystectomy with liver segmentectomy (S4b þ S5). Patients with T3
GBC usually need radical resection and T4 tumors are usually
unresectable. Qu et al12 analyzed 139 patients with GBC and
concluded that radical resection might result in a satisfactory
prognosis in patients without hepatic invasion, but it appears less
beneﬁt than palliative resection in patients complicated with he-
patic invasion. In our study, the most common treatment of GBC
was surgical removal of the GB and followed by extended surgery.
GB and pancreas share a common embryological origin, and, thus,
tumors arising from them may share some common antigens.
VariousGB tumormarkers such as CEA, CA-19-9, CA-125, and CA-242
have been studied14. So far, there are no good established serum-
based tumor markers for GBC. For instance, CA 19-9 was ﬁrst used
in pancreatic cancer and was then evaluated and found useful in the
diagnosis ofGBC27.However, CA19-9 is elevatedeven inpatientswith
gallstones, especially if there is associated cholestasis28e30. These
markers may have a role in assessing tumor burden and response to
therapy. Our study showed that serum level of CEAwas signiﬁcantly
higher in the elderly patients with GBC than young group. A further
prospective clinical study is needed to clarify whether CEA play an
important role of prognosis in elderly patients with GBC.
There are some limitations to our study. First, only a small
number of patients were included in our study because this study
was undertaken at a single institution. Second, our intervention
group was not homogeneous and was based on several interven-
tion approaches. Furthermore, clinically, patient performance sta-
tus is an importance consideration to the treatment decision. More
restricted physical status, poorer treatment result and more con-
servative treatment will favor. Even though this study concluded
C.-W. Chang et al.232that surgical treatment was important to improve elderly patients
with GBC, selection bias might exist in the treatment decision
making. It is therefore difﬁcult to determine the optimal treatment
approach. Third, we failed to identify any single isolated factor from
biochemical examination that was predictive of successful out-
comes prior to therapeutic management. From this perspective, a
further study with a prospective protocol may provide more
conclusions.
5. Conclusion
In conclusion, surgical treatment should not be denied to elderly
patients with GBC only on the basis of chronological age, despite a
lack of strong evidence of treatment efﬁcacy; of course, to improve
physicians' attitude toward treatment of elderly patients, proper
clinical trials dedicated to this subgroup should be planned.
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